LOGIN
Cindunistat not effective in slowing the progression of knee osteoarthritis
April 2013
Cindunistat not effective in slowing the progression of knee osteoarthritis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee
Ann Rheum Dis. 2013 Feb;72(2):187-95. doi: 10.1136/annrheumdis-2012-202239. Epub 2012 Nov 10Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
1457 patients were randomized to determine the effect of cindunistat hydrochloride maleate (inducible nitric oxide synthase inhibitor) on slowing the progression of knee osteoarthritis. Patients were allocated to receive 50mg cindunistat daily, 200mg cindunistat daily, or a placebo for 96 weeks, and were evaluated on the basis of joint space narrowing and clinical outcome. The results indicated th...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.